​

Tevogen Bio Stock (NASDAQ:TVGN)

OwnershipFinancialsChart
Tevogen Bio by TradingView

Previous Close

$7.51

52W Range

$3.64 - $43.65

50D Avg

$6.17

200D Avg

$10.32

Market Cap

$32.27M

Avg Vol (3M)

$14.49K

Beta

0.19

Div Yield

-

TVGN Company Profile

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

Jan 05, 2022

Website

TVGN Performance

TVGN Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-26.14M$-53.56M$-8.84M
Net Income$-26.28M$-10.11M$-60.48M
EBITDA$-26.14M$-13.14M$-58.89M
Basic EPS$-8.08$-4.68$-0.02
Diluted EPS$-8.08$-4.68$-0.02

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
ATOSAtossa Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
WHWKWhitehawk Therapeutics Inc
CGTXCognition Therapeutics, Inc.
HURATuHURA Biosciences, Inc.
MGNXMacroGenics, Inc.
TILInstil Bio, Inc.
CLNNClene Inc.
GLSIGreenwich LifeSciences, Inc.
SRZNSurrozen, Inc.